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ABSTRACT! 
Cutaneous infection of guinea pigs with herpes 
simplex-type 1 virus (HSV-1) provides an experimental 
model for the screening of potential antiviral chemo¬ 
therapeutic agents in humans. 5-iodo-5'-amino-2’,5 * - 
dideoxyuridine (AIU), a novel thymidine analog, is a 
potentially important antiviral chemotherapeutic agent 
which has been shown to inhibit the replication of 
herpes simplex-type 1 virus without causing any detectable 
host toxicity (1, 2, 3). In contrast, other nucleosides 
with demonstrated antiviral activity, such as 5-iodo- 
2’-deoxyuridine (lUdR), 5-trifluoromethyl-2'-deoxyuridine 
(F3dThd), 1-beta-D-arabinofuranosylcytosine (Ara-C), 
and 9-beta-D-arabinofuranosyladenine (Ara-A), have 
been shown to induce moderate to severe degrees of 
cytotoxicity (4, 5, 6, 7, 8). 
In the following study, the efficacy of AIU in 
the treatment of experimentally induced cutaneous 
HSV-1 infection in guinea pigs was examined and compared 
with lUdR, Ara-AMP (adenine arabinoside monophosphate), 
and lactose in a controlled, double-masked experiment. 
The results of this experiment demonstrated the 
effectiveness of AIU in the treatment of cutaneous 
HSV-1 infection in guinea pigs by a marked reduction in 
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the development of cutaneous erythema and the number of 
vesicles at the HSV-1 inoculated sites. In addition, 
the Ara-AMP and the IUdR treated groups also exhibited 
a decrease in the severity of the lesions as compared to 
the lactose treated control group. The relative potency 
of these antiviral nucleosides, defined in terms of 
the reduction of cutaneous erythema and the number 
of vesicles at the inoculated sites, ranked as follows: 
AIU, IUdR, Ara-AMP, in order of increasing potency. 
The statistical analysis of the experimental data 
documented the significance of the AIU treatment of 
HSV-1 cutaneous lesions in the guinea pigs by the above 
mentioned criteria. Similarly, the IUdR and Ara-AMP treat¬ 
ments were also found to be statistically significant. 
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5-IODO-5*-AMINO-2',5*-DIDEOXYURIDINE (AIU) THERAPY 
OF CUTANEOUS HERPES SIMPLEX-TYPE 1 VIRUS 
INFECTION IN GUINEA PIGS 
I. Structure and Composition of the Herpes Simplex Virus 
DNA core 
The herpes simplex virus (HSV) is a relatively large 
virus composed of an inner core of linear double-stranded 
DNA with a molecular weight of (99±5) x 10 daltons (9, 
10,11). The structure of the DNA core has been studied 
by electron microscopy, which showed the HSV DNA to be 
coiled in the form of a doughnut (12). The base compo¬ 
sition of the DNA, in terms of the guanine + cytosine 
content, is 67 mole percent for HSV-1 and 69 mole 
percent for HSV-2 (10, 13). Along the DNA strand, 
there are alkali-labile bonds situated at unique sites 
of both HSV-1 and HSV-2 DNA (10, 14)• Further informa¬ 
tion regarding the DNA sequences of HSV-1 and HSV-2 
has been obtained from the results of reassociation 
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kinetic studies of the DNA of HSV-1 and HSV-2. The data 
from these studies indicate that the HSV-1 DNA most 
likely contains no repetitive sequences (15). On the 
other hand, 16 percent of the HSV-2 DNA sequences have 
been found to reassociate more rapidly, thus supporting 
the theory that repetitive sequences exist in the HSV-2 
DNA. 
During the productive infection of the HSV within 
host cells, it is estimated that 50 percent of the DNA 
is transcribed (16, 17). Hence, if one assumes that 
transcripts all specify for the synthesis of proteins, 
then the HSV DNA must code the sequences of approximately 
55,000 amino acids. 
Capsid 
The DNA core of the HSV is concentrically surrounded 
by protein layers known as the capsid. The capsid of 
the HSV is composed of 162 structural subunits called 
capsomeres which form into an icosahedron (18, 19). 
In addition, the capsid of the HSV is known to contain 
spermine in amounts sufficient to neutralize 50 percent 




The unit containing the capsid and its enclosed 
nucleic acid is called the nucleocapsid, which is a 
rigid structure spanning approximately 95 to 105 nano¬ 
meters in diameter (11). External to this structure, 
the capsid incorporates additional proteins to form 
the tegument. The tegument has been found to bind 
tenaciously to the capsid, even after detergents have 
stripped the HSV of its outer envelope (21). 
Envelope 
The nucleocapsid is coated by a loose envelope 
which renders the virion impermeable to negative stain 
(22). This envelope is composed of lipids, polyamines, 
and at least 12 glycoproteins (23, 20). it is the 
qualitative and quantitative differences in the glyco¬ 
proteins of the HSV envelope which determine the 
immunologic specificity of the virus (24) . 
In addition to determining the immunologic 
specificity, the envelope also confers infectivity 
to the nucleocapsid. It has been claimed that the 
naked nucleocapsid does not absorb well to cell surfaces 
and is less stable than the enveloped nucleocapsid. 
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Obtained from either the nuclei or the virion exposed 
to lipases or lipid solvents which strip the envelope 
off the nucleocapsid, the resulting naked nucleocapsid 
are found to be noninfectious. However, an intact 
envelope may not be required for infectivity, since 
fragments of the envelope adhering to the nucleocapsid 
are sufficient to render it infectious (25, 26), De- 
proteinized HSV-1 DNA, either native or denatured, is 
also infectious (27), Even portions of the HSV DMA 
0 
from a deletion mutant lacking 4 x 10 daltons in its 
DMA has been reported to be capable of multiplying (28). 
Cellular HSV Infection 
Cellular infection by HSV can lead to either 
(1) productive infection in which biosynthesis of 
infectious progeny and subsequent cell death take place 
or (2) nonproductive infection in which part or all of 
the viral genome resides within the host without caus¬ 
ing cell death (29, 30), Productive infection of the 
HSV leads to multiplication of infectious virus progeny, 
host tissue destruction, and manifestation of the infec¬ 
tion clinically. But nonproductive infection is believed 
to be responsible for recurrent HSV infection and cancer. 
-6- 

Productive infection and replication of HSV 
Productive infection in the host cell begins 
with the initiation of infection within the host. 
The mechanism of penetration of HSV is unknown; however, 
two modes of viral entry into the host cells have been 
• postulated. One method of entry is believed to involve 
the fusion of the viral envelope with the plasma mem¬ 
brane of the host cell (31), while the other method 
is believed to be akin to pinocytosis (32). 
The entry of virus into cells is influenced by 
the temperature and the extracellular medium. It is 
known that polyanionic substances such as heparin and 
dextran sulfate inhibit HSV infection of cells (33), 
although HSV-1 is less susceptible to the effects of 
polyanionic extracellular medium than is HSV-2 (34). 
It has been postulated that polyanions may compete with 
HSV for the attachment to the receptors on the cell 
surface, thus hindering the HSV attachment and entry 
into the cell (35). 
The cell to cell transmission of HSV infection 
may occur in the absence of detectable infectious 
particles (36). The transmission is achieved by the 
fusion of the HSV infected cells with the adjacent 
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uninfected cells (37). After the entry of the virus into 
the cell, the outer protein capsid is stripped, resulting 
in a DNA-protein complex which enters the nucleus. Within 
the nucleus, the DNA becomes dissociated from the protein, 
and the viral DNA is transcribed. Forty-four percent of 
the HSV-1 DNA and twenty-one percent of the HSV-2 DNA is 
transcribed prior to the onset of DNA synthesis. The 
transcription of the viral DNA sequences is regulated such 
that some transcripts are more abundant than others (16, 17). 
The virus specified RNA is then processed and transported 
into the cytoplasm where it directs the synthesis of 
structural and nonstructural proteins of the virus at the 
free and membrane-bound polyribosomes (38, 39, 40, 41). 
These newly synthesized proteins specified by the HSV then 
migrate to the nucleus. However, a small portion of these 
proteins remains in the cytoplasm and binds to the cellular 
membranes (41). 
The structural proteins are assumed to regulate the 
synthesis of HSV DNA. The virus specified enzymes have 
been identified as thymidine kinase and DNA polymerase. 
The HSV specified thymidine kinase differs from the 
host thymidine kinase in its immunologic, electrophoretic, 
physical, and catalytic activity since HSV-thymidine kinase also 
phosphorylates deoxycytidine. Differences in these 
8- 
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properties have also been shown to exist between the HSV-1 
specified thymidine kinase and the HSV-2 specified 
thymidine kinase (42) . 
The synthesis of herpes virus nucleic acid occurs 
within the Feulgen-positive Cowdry Type A inclusion body 
found in the nucleus (41). The DNA synthesis is initiated 
along several sites of the molecule (14). The newly 
synthesized DNA fragments are not processed beyond 
the interruptions found at the unique sites. The 
viral DNA within the intranuclear space has greater 
number of alkali-labile bonds than those found in the 
nucleocapsid (14). 
The structural proteins of the virus migrate into 
the nucleus to form the capsid (41). Three types of 
capsids have been identified from electron microscopic 
studies. They are as follows: (1) capsids without DNA 
core, (2) capsids with DNA core, and (3) capsids with 
tegument adhering to the nuclear membrane. However, 
the capsids without DNA cores rarely have envelopes 
surrounding the naked capsid in the HSV-infected cells 
(43). In addition, the protein compositions of the three 
types of capsids also differ from each other (21, 43, 
44). 
The nucleocapsids become enveloped at the inner 
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lamella of the nuclear membrane at a region of de novo 
synthesis of nuclear membrane or at a site at which host 
proteins have been expelled (23, 43, 44). The inner lamella 
at the site of envelopment thickens due to the acquisition 
of a layer of protein to form the tegument. 
The enveloped virus is sequestered between the inner 
and the outer lamellae of the nuclear membrane and within 
the endoplasmic reticulum. The HSV is protected from any 
direct contact with the cytoplasm. The mode of egress 
of the HSV from the infected cell is not entirely clear. 
One theory states that the endoplasmic reticulum contain¬ 
ing the HSV forms vesicles which transport the HSV to 
the extracellular fluid (45). A second theory states that 
the endoplasmic reticulum connects the extracellular fluid 
with the perinuclear space containing the HSV and thus 
provides a pathway for the HSV to migrate from the infected 
cell (46). 
Cellular changes due to the HSV productive infection 
Productive infection of HSV drastically alters 
the infected cell’s DNA, protein, and RNA synthesis (41, 
47, 48). Inhibition of host DNA and protein synthesis 
begins with the entry of HSV into the cell and is 
complete within three to five hours. The inhibition of 
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DMA and protein synthesis is accompanied by the displace¬ 
ment of aggregates of chromatin at the nuclear membrane 
and the disaggregation of polyribosomes. Host RNA syn¬ 
thesis is altered by the productive infection of HSV. 
Ribosomal precursor RNA is decreased up to 70 percent. 
The host RNA is improperly processed, resulting in 
the degradation of methylated 45S ribosomal RNA rather 
than the normal cleavage into 18S and 28S segments. 
The remaining RNA which is processed does not enter 
the polyribosomal pool to regulate host protein syn¬ 
thesis (47). 
Other effects of productive infection by the HSV 
is manifested by the leakage of macromolecules from 
the infected cell (49, 50) and the reversal of the 
transmembrane potential from -20 mV to +10 mV in the 
infected cell (51). 
The HSV infected cells acquired new surface 
immunologic determinants which are similar to those on 
the surface of the envelope of the virus (42, 52, 53, 
54, 55, 56, 57), These infected cells form loose aggregates 
or may fuse together, thus creating a direct cell-to- 
cell contact which may faciliate the dissemination of 
the HSV infection (58, 59), 
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Recurrent HSV Infection 
A characteristic of HSV infection in humans, as 
well as nonhuman species is its ability to persist in 
the host, leading to recurrent infections localized on 
specific area of the host's body, such as the cornea, 
face, or genitals (29, 30, 60). The origin of the virus 
causing recurrent infections in the host is not usually 
apparent, although four theories have been stated to 
explain these recurrences. They are as follows: 
(1) exogenous infection} (2) endogenous infection from 
another site of the body; (3) chronic, continuous low- 
level viral multiplication near the site of involvement; 
(4) persistence of the virus in a non-replicating form 
at or near the site of recurrent infection. 
The data which supports the exogenous reinfection 
theory is based on occurrences of genital reinfection 
with exogenous HSV-2 in mice and Celius monkey (6l) . 
In humans, it is unlikely that exogenous source of virus 
is responsible for the recurrences of nongenital HSV 
infection since these recurrences correlate to such 
precipating factors as exposure to sunlight, fever, 
menstruation, hormones, or emotional stress (60, 29, 
30) . 
The theory of endogenous reinfection from another 
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site of the body is also unlikely to be the primary 
cause responsible for recurrent infections, even 
though such instances have been documented in infections 
of genitals with HSV from a recurrent oral infection 
(62). This theory cannot account for the fact that only 
a specific region of the body is involved in recurrent 
infections. 
The most convincing evidence against the theory 
of chronic, continuous low-level viral multiplication 
around the site of involvement is the failures of 
numerous attempts to isolate virus from biopsy specimens 
taken from the site of recurrences in the interim 
between recrudescences (29, 30, 60). 
The theory that the HSV persists in its non- 
infectious state at or near the site of recurrence is 
supported by findings in both animals and humans. 
HSV have been cultured from the trigeminal ganglion 
from human cadavers (63, 64). In animal studies, HSV 
have been found in the sacrosciatic spinal ganglion of 
mice and in the trigeminal ganglion of rabbits after 




II. The Epidemiologic Patterns 
of Herpes Simplex Virus Infections 
The discovery of two natural variants of HSV 
(type 1 and type 2) have made the epidemiologic pat¬ 
terns of HSV infections more meaningful. From the 
epidemiologic studies based on the detection of HSV 
antibodies (Abs) in the general population, it is 
evident that the acquisition of HSV Abs is markedly 
influenced by an individual's age and socioeconomic 
status. The incidence of finding HSV-1 Abs increases 
directly with an individual's age, beginning after 
six months of age when the transplacental Abs from 
the mother disappear from the newborn’s immunologic 
defense system. On the other hand, the presence of 
HSV-1 Abs is inversely related to one’s socioeconomic 
status. For example, the adults in the higher socio¬ 
economic group have a 30 to 50 percent chance of having 
HSV-1 Abs, while the adults in the lower socioeconomic 
group have an 80 to 100 percent chance of having HSV-1 
Abs. Similar trends exist for the incidence of HSV-2 
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Abs in the general population, although it is modified 
by the sexual behavior within each population subgroup. 
A rise of the HSV-2 Abs is found beginning at 14 years 
of age. The incidence of HSV-2 Abs in the adult 
population is 10 percent in the higher socioeconomic 
group, between 20 to 60 percent in the lower socio¬ 
economic group, 3 percent in nuns, and 100 percent 
in prostitutes -(67, 68). 
HSV is commonly transmitted by direct contact 
such as in the cases of herpes gladiatorum (69, 70, 71), 
The transmission of HSV-1 is predominately via the 
oral-respiratory route with contaminated secretions 
from host to host. The transmission of the virus the 
saliva is exemplified by the increased incidence of 
herpetic paronychia in medical and dental personnels 
exposed to patients with infected oral cavity or con¬ 
taminated tracheal catheters (72, 73, 74). 
HSV-2 is generally transmitted via contaminated 
genital secretions of symptomatic and even asymptomatic 
persons infected with HSV-2. In the newborn, the major 
source of HSV is from the mother who is infected with 
genital HSV-2 or less frequently HSV-1 (75, 76, 77, 78), 
The transmission of the virus occurs during the passage 
of the fetus through the infected birth canal in 50 
percent of such cases (77). 
-15- 
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III. Clinicopathologic Aspects of HSV Infections 
The incubation period for primary HSV-1 or HSV-2 
varies from 2 to 20 days, with an average of 6 days. 
In patients with primary HSV infections, the HSV Abs 
can be detected within the first two weeks in the IgM 
serum fraction, then followed by detection in the IgA 
and IgG fractions afterwards (79). Delayed hyper¬ 
sensitivity reaction to HSV antigens as exhibited by 
a positive skin test usually develops (80, 81). 
Dissemination of Primary HSV Infection 
The dissemination of primary HSV infection generally 
occurs only in the compromised host. The pathologic 
process of HSV dissemination have been described as 
follows (75, 82), Initally, primary viremia results 
from a spillover of the HSV from the infected cells 
located at the portal of entry. This leads to the 
spread of HSV infection to the susceptible organs. 
At this point, histopathogic changes remain minimal 
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in the infected organs. In the progressive phase of 
the infection, the viremia disappears at the same time 
that virus replicates within the target organs. This 
leads to the cellular damage in these tissues. Follow¬ 
ing this phase, a secondary viremia develops from the 
production of virus within the target organs. The 
secondary viremia leads to further spread of virus to 
involve other organ systems. This phase is followed by 
the regression and the recovery of the host from the 
HSV dissemination. 
HSV Infection in the Noncompromised Host 
HSV viremia is rarely encountered in the non¬ 
compromised host who is greater than one month of age 
(83, 84, 85). In this type of hosts, KSV infection is 
generally localized in specific target organs without 
the development of systemic dissemination. The target 
organs infected by the HSV are derived from the embryonic 
ectoderm such as the skin, oral cavity, vagina, conjunctiva, 
and nervous system. 
The factor which determines whether HSV-1 or 
HSV-2 is involved in the infection of a specific organ 
ls the mode by which the virus gains entry into the host. 
However, one cannot totally disregard the general pro¬ 
perties of each virus type in determining the tissue 
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susceptibility or the route of dissemination within 
the host. 
HSV Infection of the Oral-respiratory Tract 
Oral herpetic infections are generally caused 
by HSV-type 1,rather than HSV type 2. In children, 
the mouth is the major site of primary HSV-1 infection. 
The clinical manifestation of the HSV infection of the 
mouth in the noncompromised host varies from inapparent, 
subclinical infection to severe gingivostomatitis with 
vesicular lesions and ulcers of the mucous membrane, 
cervical adenopathy, and fever (86), Further direct 
contact transmission of the contaminated secretions 
can lead to subsequent infection of other susceptible 
organs such as the eye, genitalia, fingers, etc. On 
the other hand, primary HSV-1 infection of the mouth in 
neonates or in the compromised host can extend to the 
lungs and the esophagus with a potential for dissemina¬ 
tion to other visceral organs or the central nervous 
system (75, 87, 88, 89). 
HSV Infection of the Lios 
Primary HSV infection involving the lips is not 
common, but it is the site most commonly involved in 
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recurrent HSV lesions. The site of the lips involved 
in labial herpes is well corrolated with the site of 
lip cancer (90). Labial herpes generally heals within 
5 to 7 days without the development of extensive com¬ 
plications except in those instances involving the 
compromised hosts of Hodgkin patients (91, 92) . In 
these patients, there is a tendency for the persistence 
of the lesions or the extension of the infection locally. 
HSV Infections of the Eves 
HSV infection of the eyes is due to HSV-1 in 
primary or recurrent disease, except in the newborns 
when HSV ocular lesions are often due to HSV type 2. 
The severity of the infection is dependent on the 
depth of the lesion and the recurrent nature of the infec¬ 
tious process. The spectrum of such ocular involvement 
includes follicular conjuctivitis, superficial or 
stromal keratitis, cataracts, iridocyclitis, and pan¬ 
uveitis (93, 94, 95, 96). With severe and recurrent HSV 
ocular infections, the tissue damaged from the infection 
can markedly impair the vision of the afflicted in¬ 
dividual . 
HSV Infections of the Skin 
HSV infections of the skin generally occur in 
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a diseased, broken, or traumatized skin, but not in 
an intact skin. The skin lesions which develop from 
primary or recurrent HSV are localized vesicular lesions. 
The course of these skin Vesicular lesions is influenced 
by the immunologic status of the afflicted individuals 
In the compromised host, these skin lesions become more 
extensive and chronic in nature (91, 92). In those 
individuals having atopic eczema or dermatoses such as 
Darier's disease, the HSV vesicular lesions become more 
generalized to form Kaposi’s varicelliform eruption or 
eczema herpeticum (97). Recurrences have been described 
in such cases, although they are usually less severe 
and shorter in duration than the initial primary infection. 
In traumatic herpes lesion, the HSV enters the skin 
via a break in the epithelium of the skin from an 
abrasion, laceration, puncture or burn wound. Such skin 
lesions often occur in the fingers as herpetic whitlow (72), 
in wrestlers as herpetic gladiatorum (71, 72), and in 
burn patients who are more susceptible to systemic 
herpetic infections (88). 
Neonatal herpes can present with skin vesicles, 
although the skin lesions are sometimes absent (75), 
Occasionally, a generalized macular erythematous rash 
precedes the onset of the vesicular lesions. If the 
infected neonate survives the initial HSV infection, 
these lesions can recur at the original sites, as well 
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as new locations. 
HSV infections of the skin can be due to either 
type 1 or type 2, depending on the mode of acquisition 
of the virus. Hence, neonatal herpes is generally due 
to HSV-2; skin lesions in adults located above the waist 
is often due to HSV-1; and those lesions located below 
the waist of adults is often due to HSV-2. 
HSV Infections of the Urogenital Tract 
HSV infection of the urogenital tract is a common 
venereal disease, predominately due to HSV-2. Only 5 
to 10 percent of HSV infections of the urogenital tract 
are due to HSV-1. HSV-1 urogenital tract infections 
are mainly due to autoinfection from another site of 
the body, as seen in those cases involving HSV-1 
urogenital tract infection in children (62), 
In females, the HSV infection occurs more com¬ 
monly in the cervix than in the external genitalia 
(71, 72, 73),In the symptomatic or the asymptomatic 
males, the virus have been isolated from the penis, 
urethra, prostate and the seminal vesicles. 
The clinical manifestations of HSV genital in¬ 
fection is dependent on the presence of neutralizing 
Abs to either types of HSV. In the absence of any 
neutralizing Ab to HSV, the clinical manifestations of 
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genital HSV infections tend to be more severe. It 
may be complicated by such symptoms and signs as fever, 
constitutional signs, reginal adenopathy and dysuria. 
In addition, genital herpetic infections can be accompanied 
by pleocytosis of the cerebrospinal fluid, even in the 
absence of meningeal sings, radiculitis, or myelitis 
(83) . 
HSV Infection of the Nervous System 
HSV infection of the nervous system can manifest 
as encephalitis, meningitis, radiculitis, or myelitis 
(83, 98, 99). HSV infection of the nervous system may 
be due to a primary infection limited to the brain, or 
it may occur in disseminated HSV infections, particularly 
in the cases involving newborns. 
Studies indicate that the mode of spread of the 
HSV may differ according to the type of HSV involved 
(83). HSV-2 is thought to spread to the nervous tissue 
via the hematogenous pathway, while HSV-1 is thought 
to spread to the nervous tissue predominately via the 
neurogenic pathways. 
The type of HSV causing the infection of nervous 
tissues is dependent upon the age of the host. Except 
for newborns, these infections are commonly due to HSV-1. 
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IV. The Treatment of HSV Infections 
At the present time, there are several approaches 
available experimentally and some available clinically 
for the treatment of HSV infection in humans. Anti¬ 
metabolites composed of nucleoside analogues have 
varying degrees of effectiveness against HSV infection. 
Photodynamic inactivation using heterotricyclic dyes such 
as neutral red or proflavine is under investigation for 
the treatment of HSV infection. Immunizing agents such 
as BCG, smallpox vaccines, and most recently, inactivated 
HSV vaccines have been examined in this country as well 
as in Germany and in France. Interferon and interferon 




5-Iodo-2'-deoxyuridine (IUdR), a synthetic nucleoside 
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analogue discovered in 1959 by W.H. Prusoff, was the 
first agent used clinically for the treatment of HSV 
infection (100). The effectiveness of the topical 
administration of IUdR for the treatment of HSV infection 
of the corneal epithelium in rabbits and in humans 
has been demonstrated by several investigators (101, 
102, 103, 104, 105). Unfortunately, IUdR has proved to 
be ineffective for the treatment of herpes labialis in 
a double-masked study by Kibrick and Katz (106). 
In addition, IUdR has limited application for the 
management of cutaneous and genital herpetic infections 
due to the lack of therapeutic response and the toxicity 
on the host (98, 107). 
The antiviral activity of IUdR is believed to be the 
result of its incorporation into the viral DMA, in sub¬ 
stitution for the thymidine moiety. The incorporation 
of IUdR into the DMA of animal viruses have been estab¬ 
lished by several investigators (49, 108, 109, 110, 111, 
112). The incorporation of halogenated deoxyribonucleosides 
have been shown to inhibit the formation of infectious 
. 7 
herpesvirus particles to a ratio of 10 virus particles 
to one infectious virus (113, 114), 
The specific molecular defect responsible for these 
changes resulting from the incorporation of IUdR into 
the herpes virus DMA has not been elucidated, but Prusoff 
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and Goz have reviewed this subject extensively (115, 
116). 
The use of topical or systemic IUdR is associated 
with considerable toxic side effects. The toxicity is 
most likely a consequence of the incorporation of IUdR 
into the DNA of normal uninfected host cells. In the 
systemic administration of IUdR in patients at a con¬ 
centration of 100 mg/kg/day for 5 to 6 days, the toxic 
effects reported are stomatitis, leukopenia, and alopecia 
(117), In the topical administration of IUdR in the eyes 
of patients, ocular toxic effects such as punctate 
epithelial keratopathy, follicular conjunctivitis, 
narrowing and occlusion of the puncta, contact dermatitis^ 
lid margin changes and excess lacrimation have been re¬ 
ported (118). During corneal wound healing, toxic changes 
have been observed in the regenerating epithelium(119, 120) 
and the stromal regeneration of the cornea (119, 121) . 
In experimental models, IUdR hav been associated 
with teratogenic changes in laboratory animals. These 
teratogenic changes have been demonstrated in pregnant 
rabbits treated with topical administration of IUdR 
to the eyes at doses comparable to that used in humans 
(122). Subcutaneously injected IUdR has also been shown 
to induce teratogenic abnormalities in neonatal rats 
and mice, consisting of changes in the granular and 
-25- 

molecular layers of the external cerebellum, impaired 
nephrogenesis, ocular abnormalities such as posterior 
subcapsular cataract, retarded retinal maturation, and 
retinal dysplasia (123, 124), 
The clinical use of lUdR is further limited by the 
existence of lUdR resistant strains of HSV (125, 126) , 
The primary use of lUdR has been in herpes simplex 
Keratitis, using either ophthalmic ointment at 0,5% 
or ophthalmic solution at 0.1% concentration. 
9-Beta-D-arabinofuranosy1adenine 
9-Beta-D-arabinofuranosyladenine (Ara-A) was 
orignially synthesized in 1960 as an anti-cancer agent 
(127), Ara-A has antiviral activity against a broad 
\ 
spectrum of DNA viruses including the HSV, as well as 
some of the of the oncogenic RNA viruses such as the 
Rous Sarcoma virus and the Gross murine leukemia virus 
(128, 129, 130, 131) , 
The current clinical usefulness of Ara-A is pre¬ 
dominately in the treatment of ocular HSV infections. 
It is equally as effective as lUdR in the therapy of 
acute primary or recurrent dendritic keratitis caused 
by HSV, In addition, Ara-A can be used to treat those 
diseases caused by lUdR resistant strains of HSV (119, 
132, 133, 134, 135, 136, 137) . 
-26- 

The intravenous administration of Ara-A has been 
successfully used in the treatment of patients with 
herpes kerato-uveitis (138). Ara-A may be beneficial 
in the treatment of neonatal herpes if administered 
early in the course of the infection (139). However, 
the response of genital herpes simplex infection to 
Ara-A has been highly variable (140). Ara-A has also 
been tested in a placebo-controlled study on HSV-1 
encephalitis in humans. The results from this study 
show a reduction of the mortality rate from 70 to 28 
percent in patients with HSV-1 encephalitis when they 
were treated with Ara-A early in the course of the 
infection (141). 
The mechanism of action of Ara-A has not been 
completely elucidated. The antiviral activity of Ara-A 
may be attributed to the incorporation into the DMA 
and/or the inhibition of DMA polymerase (142, 143). 
The deaminated product of Ara-A, the hypoxanthine 
derivative of Ara-A, is approximately equal to Ara-A 
in its antiviral activity (129), 
The administration of Ara-A has been associated 
with the following toxic effects. In the systemic 
administration of Ara-A to patients with chronic 
hematologic conditions, a mild to moderate depression 
in the level of the hemoglobin was observed, without 
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any accompanying change in the neutrophils and platelet 
levels (144). Two patients with Hodgkin's disease 
receiving Ara-A at 20 mg/kg/day have been reported to 
develop a transient motor aphasia resembling akinetic 
mutism (144). Chromosomal gaps and breaks have been 
observed in leukocytes treated with in vitro Ara-A 
(145), Systemic administration of Ara-A in patients 
have also been associated with an increase in chromo¬ 
somal breakage found in the leukocytes (146)* Besides 
its toxicity, the therapeutic usefulness of Ara-A is 




or Ara-AKP, is a modified compound of Ara-A by the 
addition of a phosphate group. Its major advantage 
over Ara-A is the increased water solubility property, 
as compared to its parent compound Ara-A (147). Ara- 
\ 
AMF has been shown to have marked in vitro and in vivo 
activity against a host of DNA viruses (148, 149) . 
Other studies have demonstrated its effectiveness in 
the treatment of HSV-1 keratitis in rabbits (148, 150) , 
and in herpes virus induced cutaneous lesions in tails 
of mice (148) # 
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Preliminary toxicity studies have not shown Ara- 
AMP to be more toxic than Ara-A (151). Because of its greater 
solubility in water, Ara-AMF can be a potentially impor¬ 
tant antiviral agent that can be administered via paren¬ 
teral routes in smaller fluid loads than Ara-A. How¬ 
ever, further toxicity studies are needed prior to the 
initiation of clinical trials of Ara-AMP. 
1-Beta-D-Arabinofuranosvl Cvtosine 
1-Beta-D-Arabinofuranosyl cytosine (Ara-C), 
originally developed as an antileukemic agent, has a 
spectrum of antiviral activity similar to Ara-A. The 
antiviral potential of Ara-C has been reviewed extensively 
(4, 7, 8, 152, 153). It has been established that Ara-C 
s 
is active against experimental herpetic and vaccinia 
keratitis. However, the clinical use of Ara-C in the 
treatment of herpetic keratitis in humans is restricted, 
due to Its toxicity. Similarly, systemic use of Ara-C 
for the treatment of other herpes simplex infections are 
also restricted. The therapeutic to toxic ratio approaches 
unity for Ara-C, being 10 times more toxic than IUdR 
(154), The systemic toxicities of Ara-C include terato- 
genesis, immunosuppression, chromosomal aberration, 
leukopenia, thrombocytopenia, megaloblastosis, hepatic 
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toxicity, and gastrointestinal toxicity (155, 156, 157). 
Reports of toxic changes following the topical use of 
Ara-C in the eyes include punctate epithelial kerato¬ 
pathy, corneal ulceration, and iritis (158). 
In addition to its toxicity, Ara-C’s clinical 
usefulness is further * limited by its rapid deaminiation 
in the liver and the kidneys to uracil arabinoside, an 
inactive metabolite of Ara-C. However, the deamination 
of Ara-C is less of a concern in intrathecal administra¬ 
tions of Ara-C since deaminases are absent in the brain. 
Thus, the active form of Ara-C will persist much longer 
when intrathecal injections are given (159). 
5-Trifuoromethyl-2 *-Deoxvuridine 
5-Trifluoromethyl-2*-deoxyuridine (F3TdR) is an 
antineoplastic agent which is highly active against 
HSV (160). In contrast to IUdR, the solubility and 
the potency of FgTdR has been reported to be 10-fold 
greater than that of IUdR in the treatment of herpetic 
keratitis in rabbits. In clinical trials of F3TdR on 
herpetic keratitis, in which 1% solution of F-^TdR was 
tested against 0.1% solution of IUdR, F^TdR proved to 
be more effective than IUdR (161). When compared to 
Ara-A in the treatment of dendritic keratitis in 
humans, there was no statistical difference between 
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the use of FgTdR and Ara-A (162). 
From the extensive studies performed primarily 
with vaccinia virus, the mechanism of antiviral action 
of FgTdR is believed to be due to its incorporation 
into the virus DNA (163, 164) and its subsequent 
alteration in the transcription of late mRNA (165). 
In experimental models, bone marrow toxicity and 
teratogenic activity have been reported with the use 
of F^TdR (168, 169). F^TdR has been found to be 
mutagenic to bacteriophage but not mutagenic to 
Chinese hamster cells in culture (3). F^TdR therapy 
of herpetic keratitis has produced punctate epithelial 
erosions and epithelial microcysts when administered 
more frequently than 5 times daily for more than a few 
days. Further application of F3TdR at this point has 
produced frank epithelial edema with stromal swelling 
(118). When used topically in the eyes of rabbits, 
F^TdR has not produced teratogenic changes, unlike 
the teratogenic changes reported with topical use of 
IUdR (122). 
FgTdR, as with IUdR, is incorporated into the 
viral DNA and the uninfected host cell DNA (164). 
The toxicity of F^TdR is thought to be related to 
its incorporation into the DNA of the uninfected host 
cell and the irreversible inhibition of thymidylate 
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synthetase, an enzyme needed in the biosynthesis of 
dTMP, an essential precursor of DNA (166, 167), 
5-Trif luoromethyl-5 * -Amino-2 * , 5 * -Dideoxyuridir.e 
An analog of F^TdR is 5-trifluoromethvl-51-amino- 
2 *,5 *-dideoxyuridine, which was synthesized by Lin, 
Chai, and Irusoff in 1976 (170), Although it is four¬ 
fold less potent as an antiviral agent against KSV in 
Vero cells than its parent nucleoside, F^TdR, it is also 
40 times less toxic than F^TdR. Thus, the therapeutic 
index of F^TdR has been improved by a factor of 10 when 
modified to its 5 *-amino analog. 
5-Iodo-2'-Deoxycytidine 
V 
5-Iodo-2'-deoxycytidine or IdCyd is a precursor 
analog of lUdR which was initially synthesized in 1961 
(171), Studies performed on IdCyd demonstrated its 
effectiveness against HSV in culture (172) and in 
herpetic keratitis in rabbits (173). It is known that 
IdCyd and its bromo analog not only inhibit HSV in culture, 
but they are also substantially less toxic to the un¬ 
infected host cell than their deoxyuridine analog (174), 
The selective action of IdCyd on the virus infected 
cells is dependent on its phosphorylation by only the 
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virus induced deoxycytidine kinase. This property may 
also explain why IdCyd is more effective than IUdR 
in the treatment of experimental deep herpetic keratitis 
(175). IdCyd is not converted into its active deaminated 
derivative until it is within the virus infected cells 
and has been phosphorylated by the virus induced deoxy¬ 
cytidine kinase. Therefore, in deep herpetic keratitis, 
IdCyd is protected from being metabolized on the surface 
until it reaches the deep layers of the infected cells. 
On the other hand, the clinical efficacy of IdCyd is de¬ 
pendent on the quantity of deoxycytidine kinase within 
the virus infected cells. Although several investigators 
have found an increase in the quantity of deoxycytidine 
kinase in the HSV infected cells (176, 177), a contradictory 
report has shown no increase of deoxycytidine kinase in 
the HSV infected cells (178). In the latter case, 
IdCyd is totally ineffective as an antiviral agent. 
5-Ethvl-2 *-Deoxvuridine 
The synthesis of 5-ethyl-2*-deoxyuridine was 
reported in 1969 (179, 180). It is an inhibitor of 
the replication of both HSV and vaccinia virus in cell 
cultures (181, 182) and in experimental deep herpes 
keratitis in rabbits (184). Clinical investigations 
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of 5-ethyl-2 ’-deoxyuridine indicate a positive therapeutic 
effect in the therapy of herpetic keratitis (185, 186). 
5- Ethyl-2’-deoxyuridine is not as effective as IUdR 
or F^TdR, but its potential as an antiviral agent is 
based on its non-mutagenic effect on the studies in 
phage and drosophila (187, 188). It also has no effect 
upon the chromosome morphology of l>uman lymphocytes 
and fibroblasts in culture (189). 
Other 5-alkyl analogs of thymidine such as 5-vinyl-, 
5- propyl-, and 5-allyl-2*-deoxyuridine have been 
synthesized and shown to have antiviral activity against 
both HSV-1 and HSV-2 in cell cultures (190). 
6-Azauridine 
6- Azauridine is a broad spectrum antiviral agent 
effective against a variety of RNA and DNA viruses in 
vitro. The inhibition of HSV replication by 6-azauridine 
has been reported by several investigators (191, 192). 
6- Azauridine is similarly effective against herpes 
simplex keratitis in rabbits (191) and herpes simplex 
stromal infection of the eye in humans (193), However, 
the clinical applicability of 6-azauridine in the 
treatment of HSV infection is severely limited by its 
low potency and its toxicity. Reported cases of serious 
-34- 

central nervous system disturbance have been associated 
with the use of 6-azauridine (194). In addition, this 
antiviral agent is both immunosuppressive and teratogenic. 
1-Beta-D-Ribofuranosy1-1.2,4.-Triazole-3-Carboxamide 
1-Beta-D-ribofuranosyl-1,2,4,-triazole-3-carboxamide 
(Virazole, Ribavirin) is a broad spectrum antiviral agent 
active against RNA and DBA viruses in vitro and in vivo 
(195, 196). It has been shown to be effective in the 
treatment of experimental herpes and vaccinia keratitis 
in rabbits (197) . 
The potential of this broad spectrum compound 
in the treatment of clinical diseases is limited by 
two factors. Firstly, it must be administered as a 
prophylactic agent in order to exhibit its effectiveness 
as an antiviral agent. Secondly, teratogenesis has 
been observed with this agent (165). 
Photodynamic Inactivation of HSV Infections 
Another investigative approach to the treatment of 
HSV infections is that of photodynamic inactivation of 
HSV. The experimental works of Wallis and Kelnick 
revealed the in vitro inactivation of HSV by exposure 
to heterotricyclic dyes and light (198, 199). 
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The heterotricycle acridine and phenazine dyes are 
photoactive compounds capable of absorbing light energy 
and participating in photo-oxidation reactions. The 
phenazine compound neutral red was the first dye used 
in the photodynamic inactivation of herpes simplex skin 
infections in humans (200), Because of neutral red’s 
potential as a contact allergen (201), it has been 
replaced by the use of proflavin, an acridine dye, which 
has greater effectiveness in photosensitizing viruses 
in vitro (199), The effectiveness of photodynamic 
inactivation of viruses is dependent upon the dye 
concentration, temperature, and pH. The progeny virus 
becomes sensitive to light when grown in cells pre¬ 
treated with heterotricyclic dyes (202) . The dye is 
incorporated into the virus DNA (203), The virus is 
inactivated when the dye-DMA complex absorbs sufficient 
energy to produce an oxidation reaction, resulting in 
the loss of guanine, gaps in the- base sequence, and 
the subsequent breaks in the DMA of the virus (204) . 
In this manner, HSV can be made photosensitive by the 
incorporation of a heterotricyclic dye into its DMA so 
that subsequent exposure to visible light renders the 
HSV noninfectious, (198) , 
The use of photodynamic dyes has been successfully 
applied in the treatment of experimental herpes simplex 
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keratitis in rabbits (205, 206, 207), but it is less 
effective than that of IUdR (206). Other studies have 
reported the effectiveness of photodynamic inactivation 
of eczema herpeticum, orolabial and genital HSV infec¬ 
tions in humans (200, 208-216). However, other investi¬ 
gators have reported opposite results which failed to 
demonstrate antiviral activity in the treatment of 
genital HSV infection and in recurrent HSV infection 
(217, 218, 219). 
There are hazards associated with the use of 
photodynamic dyes,and its clinical application remains 
rather controversial. The photodynamic inactivated HSV 
have been shown to induce neoplastic transformation of 
mammalian cells in vitro (200) which have oncogenic 
properties in vivo (221). 
Interferon and Interferon Inducers 
Interferon and interferon inducers are of great 
biologic interest as potential broad spectrum antiviral 
agents. At the present time, they have not proved to be 
clinically useful in the prophylaxis or the treatment 
of viral infections. Studies of the topical application 
of human interferon in the treatment of herpetic keratitis 
are rather disappointing (222) . 
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Studies aimed at the prevention of recurrent ocular 
herpetic infections in humans with topical leucocyte 
interferon were also therapeutic failures (223) , 
Another disadvantage in using induced, systemic, 
or local interferon is the capability of the host cells 
to be stimulated only for a limited period of time 
(6 to 10 weeks), after which they need a rest period of 
3 weeks before induction could be started again (224, 225) . 
The use of inducers of interferon such as polymers of 
double-stranded RbA's (poly I--ploy C) and substituted 
propanediamin.es are just as disappointing since they 
are usually accompanied by considerable toxicity (226, 
227, 228, 229) . 
5~Iodo~5*-Amino-2 *,5 *-Dideoxyuridine 
From the previous discussion of antiviral nucleoside 
analogues, photodynamic dyes, interferon and interferon 
inducers, it is evident that none of these agents 
constitute an ideal chemotherapeutic agent against 
HSV infection in humans. The most worrisome characteris¬ 
tics of the nucleoside analogues are their low solubility 
and their toxicity to the uninfected host cells. These 
toxic side effects are presumably due to the incorpora¬ 
tion of the drugs into the nucleic acids of the uninfected 
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cells, resulting in cytotoxicity and the potential 
of inducing mutagenesis and carcinogenesis. Hence, 
an antiviral agent which is incorporated into the nucleic 
acids of only the virus infected cells and not the uninfected 
cells will provide a major advance toward minimizing the 
toxicities commonly associated with the current antiviral 
therapy. 
S-Iodo-5'-amino-2*,5'-dideoxyuridine or AIU is the 
5'-amino analog of lUdR which was originally synthesized 
in the laboratory of W.H. Prusoff at Yale University in 
1974 (230). The initial studies of AIU demonstrated 
its in vitro capability as a potent inhibitor of HSV-1. 
AIU was shown to be more potent than Ara-A but less 
potent than lUdR, F^TdS, or Ara-C on a molar basis. 
The most significant finding was the absence of any 
cytotoxicity associated with the use of AIU, as opposed 
to the toxicity observed with similar concentrations 
of lUdR, F^TdR, Ara-A, and Ara-C (2). When compared 
with Ara-A, a nucleoside analog noted for its high thera¬ 
peutic index, Ara-A was found to have significant 
toxicity at concentration that produced less anti¬ 
viral activity than AIU. 
AIU*s lack of cytotoxicity was further demonstrated 
in the following cell lines examined in culture: murine 
sarcoma 180, Erhlich ascites, BHK-21 (hamster kidney). 
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HeLa, secondary chicken embryonic fibroblasts, A-9 and 
L cells (231). In addition, AIU at 200 jiM produced no 
detectable morphological changes nor inhibited the 
normal rate of DNA and RHA synthesis of uninfected Vero 
cells (2). 
In vivo studies with the intraperitoneal administra¬ 
tion of AIU in newborn and 8 day old suckling mice 
also produced no growth retardation nor teratogenic 
effects. In contrast, IUdR administered intraperitoneally 
produced growth retardation, as well as histopathological 
evidence of cataract, retinal dysplasia, cerebellar 
lesions, cortical lesions, and general retardation of 
organ development (232). 
A study of AIU in the treatment of experimental 
herpetic keratitis in rabbits established 
its therapeutic effectiveness on experimental herpetic 
keratitis in rabbits (233). Although AIU is less potent 
than IUdR, viral recovery studies showed AIU and IUdR 
to be equally effective in reducing the titer of 
HSV-1 in the treated tissues. 
Given the experimental data documenting the thera¬ 
peutic effectiveness of AIU on HSV-1 keratitis in rabbits 
and the absence of cytotoxicity, AIU appears to be a 
promising agent which should be tested in the treatment 
of other forms of HSV-1 infections. 
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Cutaneous herpes infections are the cause of sub¬ 
stantial morbidity in the otherwise healthy population 
and can sometimes result in the mortality of newborns 
and patients with diminished immunologic competence. 
Disseminated or severely localized herpes simplex 
infections are life-threatening complications in the 
patients with hematologic malignancies or in patients 
with immunosuppressive therapy following renal trans¬ 
plantation, severe burns, malnutrition, and immune defi¬ 
ciency syndromes such as the Wiskott-Aldrich syndrome 
(92, 234, 235, 236). The occurrence of life-threatening 
HSV infections is expected to increase, due to the 
current treatment of malignancies with chemotherapeutic 
agents having significant immunosuppressive action. 
Hence, there will be an increasing need for an effective 
antiherpetic agent having minimum cytotoxicity for the 
topical or systemic treatment and prophylaxis of cutaneous 
and oral herpes simplex lesions in these patients. 
Given the preliminary studies of AIU, it appears to be 
a promising agent which should be investigated for the 
treatment of cutaneous herpes simplex infection. 
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V. Materials and Methods 
I. Drugs. 
A. IUdR was obtained from Sigma Chemical Company, 
St. Lousi, MO. 
B. AIU was synthesized in the laboratory of W.H. 
Frusoff, Professor of Iharmacology, Yale University, 
as described by Lin, et al, 1976 (1). 
C. Ara-AMF was provided by Fark-Davis Company in 
ointment form at 10 percent concentration (w/w). 
II. Preparation of the drugs. 
The drugs were prepared into ointment form by 
Al Fiore, Director of the Pharmacy Research and 
Development Department of the Massachusetts General 
Hospital, Boston, MA. 
A. 5 gm. IUdR was mixed into petrolatum base to 
make an IUdR ointment at 0.5% concentration (w/w). 
The IUdR ointment was then loaded into 70 tuberculin 
syringes (1 ml.) to yield a total of 70 ml. of 
0.5% IUdR ointment. 
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B. 9 gm. AIU was mixed into a petrolatum base to 
make an AIU ointment at 10% concentration (w/w). 
The AiU ointment was then loaded into 70 tuberculin 
syringes (1 ml.) to yield a total of 70 ml. of 
10% AIU ointment. 
C. 15 tubes of 3.55 gm. of Ara-AMP ointment at 10% 
concentration (w/w) was provided by tark-Davis 
Company. The Ara-AMP ointment was loaded into 
50 tuberculin syringes to yield 50 ml. of Ara-AMP 
ointment. 
D. 70 ml. of 10% (w/w) lactose ointment, as prepared by 
A1 Fiore, was loaded into 70 tuberculin syringes. 
The tuberculin syringes containing the drugs were 
coded by a member of the laboratory who was not 
involved in the daily examination and the grading 
of the HSV cutaneous lesions of the guinea pigs. 
The drugs were labeled as drug A, B, C, and D. The 
drug code was not known to the investigators until 
the experiment had been completed. 
III. Guinea Iiqs. 
A total of 21 adult male Hartley strain guinea pigs 
were used, each weighing between 300 and 500 grams. 
The guinea pigs within the same treatment group 
were kept in the same cage. Daily feeding of the 
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guinea pigs and maintenance care of the cages were 
provided. 
IV. Herpes Simplex Virus - Type 1 
The HSV-1 was provided by E-ravin Bhatt at Yale 
University. The HSV-1 used in the experiment was 
NIH strain No. 11124, contained in a solution of 
10 TCID^g/ml. The virus solution was kept frozen 
until the time of inoculation. 
V. Procedures 
The hair on the dorsum of the guinea pigs was shaved 
using electric clippers. A chemical depilatory 
(Nair, Carter Products, N.Y.) was applied on the 
moistened, shaved area of the guinea pig dorsum 
for 10 minutes. The shaved area was then rinsed 
with warm water to remove the depilatory. The 
shaved area of the guinea pig dorsum was dried 
with soft towels. Using indelible ink 
pens, the shaved dorsum was marked into a grid of 
six squares, each square measuring 2 cm. x 2 cm. 
The guinea pigs were then anesthesized using 0.4 ml. 
of sodium pentobarbital injected intraperitoneally. 
While the guinea pigs were under the sodium pento¬ 




at 10 TCID^q/itiI . was applied topically to the surface 
of the guinea pig at each square of the grid, using a 
tuberculin syringe to measure the HSV-1 solution. The 
HSV-1 was then inoculated intradermally with a spring- 
loaded vaccination instrument (Sterneedle, Ian Ray Divi¬ 
sion, Ormond Drug, Englewood, lew Jersey), 10 times in 
each square. The spring-loaded vaccination instrument 
produced a ring of six inoculation site to a depth of 
0.75 mm. 
After the intradermal inoculation of the HSV-1, the 
guinea pigs were randomly distributed into four treatment 
groups as follows: 
Drug A- -five guinea pigs 
Drug B- -five guinea pigs 
Drug C- -six guinea pigs 
Drug D- guinea pigs 
The drug treatment was begun immediately after the 
inoculation of HSV-1. 0.1 ml. of ointment from the 
tuberculin syringes was applied topically to each square 
of the grid and was gently rubbed onto the entire surface 
of the square. After the drug application, the guinea 
pigs were returned to their respective cages. The 
treatment schedule was repeated every 8 hours for 6 
consecutive days. 
During the morning treatment sessions, two investigators 
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independently grade the lesions on each guinea pig before 
the treatment was begun. These two investigators did 
not know the drug code until the termination of the 
experiment. 
Each guinea pig was examined daily for 11 days by 
the two investigators, starting 1 day after the intra- 
dermal inoculation of HSV-1. The development of the 
HSV-1 lesions in each square was evaluated by the 
criteria of: 
1. Erythema* graded on a scale of 0 to 4, based on 
the intensity and the area of erythema. 
0 = no erythema 
1 = slight erythema:involving a small 
area 
2 = moderate erythema:either greater 
v intensity of erythema than in (1) 
or extension of the area of erythema 
found in (1) 
3 = moderately severe erythemasgreater 
intensity of erythema than in (2) 
and/or extension of the area of 
erythema found in (2) 
4 = severe erythemajgreatest intensity 
of erythema compared to that found 
in (1), (2), and (3). The area of 
erythema greater than in (3) 
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2. Vesicles s graded on a scale of 0, 1, 2, 3, . ..; 
corresponding to the number of vesicles 
found in each square. 
The guinea pig hair regrew within 5 days, necessita¬ 
ting another application of chemical depilatory on day 5 
on the dorsum of the guinea pigs, as described previously. 
Histopathologic studies 
One guinea pig in each treatment group was selected 
on day 6 for the biopsy of the skin lesions for histo¬ 
pathologic studies. The lesion was biopsied, by Using a 
disposable 3 mm. diameter Chester Baker Skin biopsy Punch. 
The biopsied specimen was then preserved in a formalde¬ 
hyde solution. The histology slides were prepared by the 
Fathology Laboratory at the Massachusetts Eye and Ear 




In this controlled, double-masked experiment, the 
HSV-1 inoculated guinea pigs were randomly distributed 
into four treatment groups. Each guinea pig was examined 
daily for the development of the HSV-1 lesions. The HSV-1 
cutaneous lesions were graded for 10 days by two independent 
investigators, according to the criteria of 
(1) erythema 
(2) vesicles 
in the manner described in the procedures. 
Each of the four treatment groups had five guinea 
pigs within each group (Notes one of the groups had 6 
guinea pigs, but one of the guinea pigs died from trauma 
sustained during one of the procedures on day 5 of the 
experiment). With 5 guinea pigs per treatment group 
and 6 HSV-1 inoculation sites per guinea pig, there were 
30 lesion sites which were examined daily in each treatment 
group. 
Since each lesion was independently evaluated by 
the two investigators, 60 lesion scores were recorded 
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for each criterion per treatment group per day. Given 
the 4 treatment groups in the experiment, a total of 
240 lesion scores were recorded per criterion per day 
for all 4 treatment groups. For the two criteria to be 
evaluated, a total of 480 lesion scores were recorded per 
day for the 4 treatment groups. Over the course of 10 
days, there were 4,800 lesion scores recorded for the 4 
treatment groups. 
In order to evaluate the efficacy of the 4 drug 
treatments on HSV-1 cutaneous lesions in the guinea pigs, 
it was necessary to simplify the 4,800 lesion scores by 
consolidating this data in the form of mean lesion score 
for each criterion per treatment group per day. The mean 
scores of the HSV-1 cutaneous lesions of the guinea pigs 
are tabulated in Table 1 for the mean erythema score and 
in Table 3 for the mean vesicle score. 
In this controlled, double-masked experiment on the 
efficacy of AIU treatment on cutaneous HSV-1 lesions in 
guinea pigs, none of the guinea pigs developed zosteriform 
distribution of the HSV-1 lesions nor manifested any 
neurologic signs such as limb paralysis or encephalitis. 
The HSV-1 cutaneous lesions which developed progressed 
from an area of erythema to vesicle formation, then 
crusting of the vesicles and finally healing of the lesions 
by day 11. 
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From the raw data, as well as from the calculated 
mean scores of erythema shown in Table 1, it is evident 
that one day after the HSV-1 inoculation, the inoculated 
sites became slightly erythematous (mean erythema score 
£l.68). By days 5 and 6, all 4 treatment groups had attained 
the maximum mean erythema score (*£2.27). After the 6th 
day post HSV-1 inoculation, the mean erythema scores prog¬ 
ressively declined until the termination of the experiment 
on the 11th day (<0.15). See Plate 1, depicting 3 
erythematous lesions at 3 inoculated sites on the 3rd day 
(erythema score = 1). 
Although all 4 treatment groups demonstrated similar 
trends in the development of erythema at the inoculated 
sites, the AIU and the Ara-AKF treatment groups differed 
somewhat in that an initial rise of the mean erythema 
scores occurred on day 1, which then subsided by days 
2 and 3. This was followed by a second rise of the mean 
erythema scores on days 5 and 6 to produce their maximum 
scores. See Figure 1 for the graph of the mean erythema 
score for the 4 treatment groups. 
Even though the trends for the development of 
erythema were similar in all 4 treatment groups, the 
actual values of the mean erythema scores differed in 
each of the treatment groups. This is exemplified by 
the cumulative mean erythema scores of the four treatment 
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groups (see Table 2). From the graph of the cumulative 
mean erythema scores shown in Figure 2, it is clear that 
the lactose group (control) had a greater cumulative mean 
erythema score than the other 3 treatment groups. In 
increasing order of magnitude, the cumulative mean erythema 
scores are : Ara-AMF IUdR <AIU^ Lactose. 
The data of the mean vesicular scores, as tabulated 
in Table 3 and graphed in Figure 3, showed that the 
development of vesicles began on day 3 in all 4 treatment 
groups. These vesicles initially develped as small, 
discrete vesicles, surrounded by an erythematous base 
(see Plate 2). The vesicles gradually enlarged in size, 
with some of the ju^posed vesicles coalescing to form 
larger, confluent vesicular lesions by the 6th day (see 
Plate 3). The fully developed lesions, which consisted 
of discrete and coalescing vesicles on an erythematous 
base, began to show signs of crusting by day 7 (see Plate 4). 
The crusting of the lesions progressed from day 7 to day 10 
in all 4 treatment groups (see plate 5). By the 11th day, 
all the vesicular lesions had healed as shown in Plate 6 
(mean vesicular score = 0.00). 
The trend observed in the mean vesicular scores for 
the 4 treatment groups differed somewhat among the groups 
in terms of the time the maximum number of vesicles developed 
(see Figure 3). That is, the maximum number of vesicles 
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developed on the 4th day for AIU, on the 6th day for lUdR, 
on the 7th day for Lactose, and on the 8th day for Ara-AMF. 
Although the 4 treatment groups had all their vesicles 
healed by the 11th day, some treatments accelerated and 
others delayed the onset of the development of the 
maximum number of vesicles by a few days. 
The cumulative mean vesicular scores for the 4 
treatment groups are similar to the cumulative mean 
erythema scores (see Figure 4). Once again, the lactose 
treated group (control) had the highest cumulative mean 
vesicular score, as compared to AIU, Ara-AMF, and IUdR. 
The calculated values of the cumulative mean vesicular 
scores are tabulated in Table 4. The cumulative mean 
vesicular scores of the 4 treatment groups are in order 
of increasing value: Ara-AMF< IUdR< AIU< Lactose. 
Statistical analysis: 
The guinea pigs in the lactose treatment group 
provided the control group for this experiment. From 
the data on the mean erythema score and the mean vesicular 
score, it is evident that the lactose treatment was not 
as effective as the other 3 treatments for HSV-1 cutaneous 
lesions in guinea pigs. This is best depicted in Figures 
2 and 4 where their respective cumulative scores are 
graphed, showing the lactose group having the greatest 
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score in both criteria. The differences between the control 
group and the other 3 treatment groups are significant: 
Mean Erythema Score: 
1. Lactose and AIU: minimum modifi ed%*17.9112 
2. Lactose and IUdR: min. mod.%1 77.0324 




Mean Vesicular Score: 
-X 
1. Lactose and AIU: minimum modified8.4237 
2. Lactose and IUdR: min. mod.OC* 69.5720 




This statistical analysis demonstrates a significant 
treatment effect of AIU, IUdR, and Ara-AMP on the development 
of erythema and vesicles in the experimentally induced 




There is no satisfactory agent available for the 
clinical treatment of cutaneous herpes simplex infections 
in humans in the United States at this time. Antiviral 
agents with therapeutic effectiveness that are available 
experimentally hav? thus far proved to be either teratogenic, 
mutagenic, or too cytotoxic to be used clinically. It is 
evident that a critical need exists for a clinically effective 
agent against cutaneous herpes simplex infection which also 
does not produce intolerable toxic effects. 
Cutaneous herpes simplex infections have been studied 
in the past, using a variety of species and inoculation 
routes. Studies of cutaneous herpes simplex infections 
have been reported using the inoculation of HSV info the 
ear of mice (237), into the skin of guinea pigs (238), into 
the skin of rabbits (239, 240), into the skin of rabbits 
with 1% hyaluronidase (241), into the footpad of guinea 
pigs (242), into the skin of mice (243), into the skin 
of hairless mice (244, 245, 246, 247), and into the skin 
of rats (248). 
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Most of these models have not been totally satis¬ 
factory since they failed to produce localized, recurrent 
lesions of HSV of the skin which simulate the course of 
the disease in humans. Another problem encountered in 
these models has been the high incidence of generalized 
herpes simplex infection, leading to herpes encephalitis, 
paralysis, and death following the intradermal inoculation 
of HSV. Others have reported the development of segmental, 
zosteriform distribution of the herpes simplex vesicles, 
with evidence of virus spread along the peripheral nerves 
(247). 
The inoculation technique of intradermal HSV described 
by Hubler, et al., in 1974 has none of the above deficiencies 
(238). This inoculation technique was successfully used 
in this study to inoculate the guinea pigs with intradermal 
HSV-1. None of the guinea pigs in this study developed 
any signs of generalized herpes simplex infection, herpes 
encephalitis, paralysis, or zosteriform distribution of 
the cutaneous lesions. The progression of the herpes 
lesions simulated the course of cutaneous herpes lesions 
found in humans. Given this experimental model for 
cutaneous herpes simplex lesions, we were able to test 
the efficacy of AIU for the therapy of herpes simplex 
cutaneous infection in guinea pigs. 
AIU is a thymidine analogue differing from IUdR 
by the substitution of an amino group for 5* hydroxyl. 
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AIU has been shown in previous studies to inhibit the in 
vitro replication of HSV-1 (2), as well as to be efficacious 
in the treatement of herpes simplex keratitis in rabbits 
(240). 
The present controlled, double-masked experiment 
demonstrates a significant treatment effect of AIU in 
the therapy of cutaneous herpes simplex infection in 
guinea pigs. The critical difference between AIU and the 
other antiviral nucleoside analogues is the absence of any 
detectable teratogenic or cytotoxic effects associated with 
the use of AIU (231, 232). This finding seems to suggest 
a virus-specified site of inhibition as the basis of its 
antiviral action. The supporting evidence for this theory 
comes from the findings listed below: 
1. The critical time of action of AIU appears to be 
during the replication of HSV within the host cell. 
The pre-incubation of HSV with AIU prior to in 
vitro infection or the presence of AIU in the media 
during the absorption process did not inhibit the 
production of virus. Only when AIU was added 4 to 
6 hours after infection was there a marked reduction 
in the yield of progeny virus (2). 
2. AIU has no inhibitory effect on the rate of RNA 
and protein synthesis in either the HSV-infected 
Vero cells or the uninfected Vero cells. More 
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importantly, AIU does inhibit the uptake of labeled 
thymidine into the ENA of HSV-infected Vero cells, 
but not in the uninfected Vero cells (2). 
3. AIU is metabolized in vitro by only HSV infected cells. 
After its conversion to the 5*-triphosphate, it is 
incorporated into both viral and cellular DNA of the 
infected cells. AIU appears to be selectively phos- 
phorylated in HSV-infected cells, mediated by the 
HSV specified thymidine kinase (249). 
4. HSV mutants defective in thymidine kinase are totally 
resistant to AIU. 
The selective phosphorylation of AIU and its incorpora¬ 
tion into the DNA of the infected cell could certainly account 
for its specific antiviral activity and its absence of host 
toxicity. This important characteristic of AIU differentiates 
it from all the other antiviral agents as a potential drug 
in the treatment of HSV infections in humans. 
This study has shown the effectiveness of AIU on one 
type of HSV-1 infection, that of cutaneous HSV-1 infection 
in guinea pigs. Further investigations on the efficacy of 
AIU on other forms of HSV infections will be worthwhile, 
particularly those HSV infections presenting as life-threat¬ 
ening disseminated infections of the newborn and the iramuno- 
suppressed patients. The possible role of AIU in the treat¬ 
ment of recurrent HSV infection, herpes encephalitis, and 




1. Significant treatment effect of AIU on experimentally 
induced herpes simplex virus type 1 cutaneous lesions in 
guinea pigs was demonstrated. 
2. Significant treatment effect of IUdR and Ara-AMP 
on experimentally induced herpes simplex virus type 1 
cutaneous lesions in guinea pigs was also demonstrated. 
3. The potency of thesethree drugs, in order of increasing 
potency as follows: 
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ERYTHEMA - MEAN LESION SCORE /DAY 
Days after 
Inoculation AIU Ara-AMP IUdR Lactose 
1 1.68 0.85 0.49 0.43 
2 0.75 0.50 0.70 0.76 
3 1.04 0.33 0.91 1.05 
4 1.10 0.86 1.16 1.42 
5 2.20 0.95 1.21 2.25 
6 1.46 1.76 1.67 2.27 
7 0.92 0.84 1.22 2.10 
8 0.77 0.72 0.73 1.33 
10 0.33 0.43 0.05 0.72 




ERYTHEMA - CUMULATIVE MEAN LESION SCORE/DAY 
Days After 
Inoculation AIU Ara-AMF IUdR Lactose 
1 1.68 0.85 0.49 0 .43 
2 2.43 1.35 1.19 1 .19 
3 3.47 1.68 2.10 2 .24 
4 4.57 2.53 3.25 3 . 66 
5 6.77 3.48 4.46 5 .91 
6 8.23 5.24 6.12 8 .18 
7 9.15 6.08 7.35 10 .28 
8 9.92 6.80 8.08 11 . 61 
10 10.25 7.23 8.13 12 .33 




VESICLES - MEAN LESION SCORE/DAY 
Days After 
Inoculation AIU Ara-AML IUdR Lactose 
1 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 
3 1.33 0.12 1.03 1.12 
4 2.28 0.90 1.53 1.97 
5 2.23 0.45 1.71 2.92 
6 2.03 0.79 1.89 3.56 
7 2.33 0.81 1.69 3.88 
8 2.35 1.71 1.17 2.26 
10 1.34 1.57 0.57 1.72 




VESICLES - CUMULATIVE MEAN VESICULAR SCORE 
Days After 
Inoculation AIU Ara-AMF lUdR Lactose 
1 0.00 0.00 0.00 0.00 
2 0.00 0.00 0.00 0.00 
3 1.33 0.12 1.03 1.12 
4 3.62 1.02 2.56 3.08 
5 5.85 1.47 4.27 6.00 
6 7.88 2.25 6.16 9.56 
7 10.22 3.06 7.84 13.44 
8 12.57 4.78 9.01 15.69 
10 13.91 6.35 9.58 17.42 
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Plate 1 i Erythematous lesions (erythema score = 1) 
at 3 inoculated sites of guinea pig 
skin on the 3rd day after HSV-1 inoculation. 
-90- 

Plate 2 i Small, discrete vesicles surrounded by an 
erythematous base found at the inoculated 




Plate 3 * Juxtaposed vesicles have coalesced to 
form larger, confluent vesicular lesions 
at 2 inoculation sites of guinea pig 
skin at 6 days post HSV-1 inoculation. 
92 

Plate 4 * The vesicular lesions of guinea pig skin 
demonstrate the initial signs of crusting, 




Plate 5 « Crusting of the HSV-1 lesions found in 




Plate 6 : On the 11th day post HSV-1 inoculation, 
the lesions have completely healed at 
the HSV-1 inoculated sites of the 
guinea pig skin. 
95 

Plate 7 i Histology of guinea pig skin infected 
with herpes simplex virus type 1 at 6 
days after virus inoculation, demonstrat¬ 
ing the ballooning degeneration of epidermal 




Plate 8 i Histology of guinea pig skin infected 
with herpes simplex virus type 1 at 6 
days after virus inoculation, demon¬ 
strating the ballooning degeneration 
of epidermal cells and the red viral 
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